Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.
This report contains market size and forecasts of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in Global, including the following market information:
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Transthyretin Stabilizers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment include Pfizer Inc, GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, Inc and Corino Therapeutics, Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Type, 2021 (%)
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Application, 2021 (%)
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc